
Quarterly report 2022-Q1
added 12-23-2023
Natus Medical Incorporated Retained Earnings 2011-2026 | NTUS
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Natus Medical Incorporated
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 84.5 M | 71.3 M | 87.9 M | 102 M | 129 M | 149 M | 107 M | 68.9 M | 34.5 M | 11.6 M | 7.17 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 149 M | 7.17 M | 77.6 M |
Quarterly Retained Earnings Natus Medical Incorporated
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 86.4 M | 84.5 M | 82.7 M | 77.2 M | 73.7 M | 71.3 M | 66.1 M | 75.4 M | 84.3 M | 87.9 M | 87.9 M | 87.9 M | 87.9 M | 102 M | 102 M | 102 M | 102 M | 129 M | 129 M | 129 M | 129 M | 149 M | 149 M | 149 M | 149 M | 107 M | 107 M | 107 M | 107 M | 68.9 M | 68.9 M | 68.9 M | 68.9 M | 36.4 M | 34.5 M | 34.5 M | 34.5 M | 13.3 M | 11.6 M | 11.6 M | 11.6 M | 9.44 M | 7.17 M | 7.17 M | 7.17 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 149 M | 7.17 M | 77.7 M |
Retained Earnings of other stocks in the Medical devices industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acutus Medical
AFIB
|
-600 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
-15.7 M | - | 3.58 % | $ 2.21 M | ||
|
Alphatec Holdings
ATEC
|
-1.42 B | $ 13.93 | 5.85 % | $ 2.09 B | ||
|
Apollo Endosurgery
APEN
|
-337 M | - | - | $ 475 M | ||
|
AxoGen
AXGN
|
-307 M | $ 32.5 | -8.14 % | $ 1.5 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-533 M | - | - | $ 1.77 B | ||
|
Avinger
AVGR
|
-421 M | - | -20.74 % | $ 369 K | ||
|
Aziyo Biologics
AZYO
|
-176 M | - | 1.37 % | $ 20.5 M | ||
|
Bio-Rad Laboratories
BIO
|
7.42 B | $ 268.7 | - | $ 7.58 B | ||
|
BIOLASE
BIOL
|
-317 M | - | -13.19 % | $ 166 K | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-185 M | - | -5.86 % | $ 30.6 M | ||
|
Cognyte Software Ltd.
CGNT
|
-157 M | $ 6.39 | 0.79 % | $ 459 M | ||
|
Axonics Modulation Technologies
AXNX
|
-374 M | - | - | $ 3.31 B | ||
|
Apyx Medical Corporation
APYX
|
-54.4 M | $ 3.54 | -0.84 % | $ 123 M | ||
|
Conformis
CFMS
|
-581 M | - | - | $ 16.4 M | ||
|
ClearPoint Neuro
CLPT
|
-191 M | $ 14.55 | -1.42 % | $ 393 M | ||
|
EDAP TMS S.A.
EDAP
|
-82.6 M | $ 4.47 | -1.11 % | $ 167 M | ||
|
Cardiovascular Systems
CSII
|
-424 M | - | 0.15 % | $ 844 M | ||
|
Bruker Corporation
BRKR
|
2.41 B | $ 39.77 | 0.53 % | $ 5.93 K | ||
|
BioSig Technologies
BSGM
|
-255 M | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
5.57 B | $ 75.15 | - | $ 111 B | ||
|
CryoLife, Inc.
CRY
|
20 M | - | -4.14 % | $ 702 M | ||
|
Dynatronics Corporation
DYNT
|
-40.5 M | - | 14.99 % | $ 929 K | ||
|
Electromed
ELMD
|
21.2 M | $ 23.15 | -5.16 % | $ 196 M | ||
|
CONMED Corporation
CNMD
|
589 M | $ 46.06 | - | $ 1.43 B | ||
|
Second Sight Medical Products
EYES
|
-122 M | - | -0.97 % | $ 54.4 M | ||
|
Soliton, Inc.
SOLY
|
-70.6 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-56.2 M | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-119 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
-39.3 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-395 M | - | - | $ 111 M | ||
|
GBS
GBS
|
-62.5 M | - | -0.57 % | $ 7.12 M | ||
|
Cutera
CUTR
|
-303 M | - | -10.19 % | $ 1.99 M | ||
|
Delcath Systems
DCTH
|
-532 M | $ 9.95 | 2.16 % | $ 284 M | ||
|
Intersect ENT, Inc.
XENT
|
-303 M | - | - | $ 955 M | ||
|
LivaNova PLC
LIVN
|
-903 M | $ 69.05 | 1.02 % | $ 3.75 B | ||
|
Eargo
EAR
|
-514 M | - | - | $ 10.2 M | ||
|
InMode Ltd.
INMD
|
969 M | $ 13.98 | -1.55 % | $ 904 M | ||
|
IRadimed Corporation
IRMD
|
56.8 M | $ 99.09 | -1.92 % | $ 1.26 B | ||
|
Establishment Labs Holdings
ESTA
|
-445 M | $ 79.67 | 6.28 % | $ 2.24 B | ||
|
Invacare Corporation
IVC
|
-78.4 M | - | - | $ 24.7 M | ||
|
FONAR Corporation
FONR
|
-33.6 M | $ 18.57 | -0.11 % | $ 122 M | ||
|
Pulmonx Corporation
LUNG
|
-468 M | $ 1.51 | 2.03 % | $ 59.1 M | ||
|
Globus Medical
GMED
|
1.39 B | $ 91.88 | - | $ 12.4 B | ||
|
Helius Medical Technologies
HSDT
|
-160 M | $ 1.85 | -1.6 % | $ 1.12 M | ||
|
Myomo
MYO
|
-88.8 M | $ 0.65 | -5.24 % | $ 4.58 M | ||
|
Medtronic PLC
MDT
|
31.5 B | $ 96.75 | - | $ 124 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
940 M | $ 11.53 | -1.96 % | $ 888 M |